KL∗VS heterozygosity reduces brain amyloid in asymptomatic at-risk APOE∗4 carriers
- PMID: 33610961
- PMCID: PMC8122023
- DOI: 10.1016/j.neurobiolaging.2021.01.008
KL∗VS heterozygosity reduces brain amyloid in asymptomatic at-risk APOE∗4 carriers
Abstract
KLOTHO∗VS heterozygosity (KL∗VSHET+) was recently shown to be associated with reduced risk of Alzheimer's disease (AD) in APOE∗4 carriers. Additional studies suggest that KL∗VSHET+ protects against amyloid burden in cognitively normal older subjects, but sample sizes were too small to draw definitive conclusions. We performed a well-powered meta-analysis across 5 independent studies, comprising 3581 pre-clinical participants ages 60-80, to investigate whether KL∗VSHET+ reduces the risk of having an amyloid-positive positron emission tomography scan. Analyses were stratified by APOE∗4 status. KL∗VSHET+ reduced the risk of amyloid positivity in APOE∗4 carriers (odds ratio = 0.67 [0.52-0.88]; p = 3.5 × 10-3), but not in APOE∗4 non-carriers (odds ratio = 0.94 [0.73-1.21]; p = 0.63). The combination of APOE∗4 and KL∗VS genotypes should help enrich AD clinical trials for pre-symptomatic subjects at increased risk of developing amyloid aggregation and AD. KL-related pathways may help elucidate protective mechanisms against amyloid accumulation and merit exploration for novel AD drug targets. Future investigation of the biological mechanisms by which KL interacts with APOE∗4 and AD are warranted.
Keywords: APOE4; Alzheimer's disease; Amyloid; Heterozygosity; KLOTHO; PET; Pre-clinical.
Copyright © 2021 Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosure statement
The authors report no conflicts of interest.
Similar articles
-
Interaction between KLOTHO-VS Heterozygosity and APOE ε4 Allele Predicts Rate of Cognitive Decline in Late-Onset Alzheimer's Disease.Genes (Basel). 2023 Apr 15;14(4):917. doi: 10.3390/genes14040917. Genes (Basel). 2023. PMID: 37107675 Free PMC article.
-
Association of Klotho-VS Heterozygosity With Risk of Alzheimer Disease in Individuals Who Carry APOE4.JAMA Neurol. 2020 Jul 1;77(7):849-862. doi: 10.1001/jamaneurol.2020.0414. JAMA Neurol. 2020. PMID: 32282020 Free PMC article.
-
KL-VS heterozygosity is associated with lower amyloid-dependent tau accumulation and memory impairment in Alzheimer's disease.Nat Commun. 2021 Jun 22;12(1):3825. doi: 10.1038/s41467-021-23755-z. Nat Commun. 2021. PMID: 34158479 Free PMC article.
-
KLOTHO heterozygosity attenuates APOE4-related amyloid burden in preclinical AD.Neurology. 2019 Apr 16;92(16):e1878-e1889. doi: 10.1212/WNL.0000000000007323. Epub 2019 Mar 13. Neurology. 2019. PMID: 30867273 Free PMC article.
-
Neuroimaging biomarkers for Alzheimer's disease in asymptomatic APOE4 carriers.Rev Neurol (Paris). 2013 Oct;169(10):729-36. doi: 10.1016/j.neurol.2013.07.025. Epub 2013 Sep 6. Rev Neurol (Paris). 2013. PMID: 24016463 Review.
Cited by
-
Oligodendrocyte progenitor cells in Alzheimer's disease: from physiology to pathology.Transl Neurodegener. 2023 Nov 14;12(1):52. doi: 10.1186/s40035-023-00385-7. Transl Neurodegener. 2023. PMID: 37964328 Free PMC article. Review.
-
The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment: A review of ADNI studies from 2021 to 2022.Alzheimers Dement. 2024 Jan;20(1):652-694. doi: 10.1002/alz.13449. Epub 2023 Sep 12. Alzheimers Dement. 2024. PMID: 37698424 Free PMC article. Review.
-
Longevity factor klotho enhances cognition in aged nonhuman primates.Nat Aging. 2023 Aug;3(8):931-937. doi: 10.1038/s43587-023-00441-x. Epub 2023 Jul 3. Nat Aging. 2023. PMID: 37400721 Free PMC article.
-
Interaction between KLOTHO-VS Heterozygosity and APOE ε4 Allele Predicts Rate of Cognitive Decline in Late-Onset Alzheimer's Disease.Genes (Basel). 2023 Apr 15;14(4):917. doi: 10.3390/genes14040917. Genes (Basel). 2023. PMID: 37107675 Free PMC article.
-
Association of Klotho Protein Levels and KL-VS Heterozygosity With Alzheimer Disease and Amyloid and Tau Burden.JAMA Netw Open. 2022 Nov 1;5(11):e2243232. doi: 10.1001/jamanetworkopen.2022.43232. JAMA Netw Open. 2022. PMID: 36413367 Free PMC article.
References
-
- Bejanin A, Schonhaut DR, Joie R. La, Kramer JH, Baker SL, Sosa N, Ayakta N, Cantwell A, Janabi M, Lauriola M, Neil JPO, Gorno-tempini ML, Miller ZA, Rosen HJ, Miller BL, Jagust WJ, Rabinovici GD, 2017. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer’s disease. Brain 140, 3286–3300. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 AG063689/AG/NIA NIH HHS/United States
- CIHR/Canada
- MR/L016311/1/MRC_/Medical Research Council/United Kingdom
- K23 AG062750/AG/NIA NIH HHS/United States
- P50 AG047366/AG/NIA NIH HHS/United States
- WT_/Wellcome Trust/United Kingdom
- MC_UU_12019/1/MRC_/Medical Research Council/United Kingdom
- R01 AG060747/AG/NIA NIH HHS/United States
- MC_UU_12019/3/MRC_/Medical Research Council/United Kingdom
- P30 AG066515/AG/NIA NIH HHS/United States
- P01 AG036694/AG/NIA NIH HHS/United States
- U01 AG024904/AG/NIA NIH HHS/United States
- R01 AG066206/AG/NIA NIH HHS/United States
- 200109/Z/15/Z/WT_/Wellcome Trust/United Kingdom
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical